Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

Sundar Jagannath, Brian G.M. Durie, Jeffrey Lee Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

High-quality response to multiple myeloma (MM) therapy can be predictive for improved outcomes. Novel agents may improve the depth of responses and therefore prolong survival. We report on the extended follow-up of a phase II study in frontline MM of bortezomib alone and in combination with dexamethasone. Forty-nine previously untreated, symptomatic MM patients received bortezomib 1.3 mg/m2, days 1, 4, 8, 11, for up to six 3-week cycles. High-dose dexamethasone was added for patients not reaching either a partial response after cycle 2 or a complete response (CR) after cycle 4. The overall response rate in 48 evaluable patients was 90%, with 42% achieving at least a very good partial response, of which 19% were CR/near CR. Thirty-six patients received high-dose dexamethasone with 28 (77%) showing improved response. Twenty-seven patients have undergone successful stem-cell transplantation (SCT). After median follow-up of 49 months, 15 patients have died; median overall survival has still not been reached, with an estimated survival at 4 years of 67%. Overall survival with and without SCT was not different (P = 0.54). Grade 3/4 adverse events included neutropenia (10%), sensory neuropathy (6% grade 3), neuropathic pain (4% grade 3), and diarrhoea (4% grade 3). Bortezomib ± dexamethasone is an effective and well-tolerated induction regimen for the frontline treatment of MM.

Original languageEnglish (US)
Pages (from-to)619-626
Number of pages8
JournalBritish Journal of Haematology
Volume146
Issue number6
DOIs
StatePublished - 2009
Externally publishedYes

Keywords

  • Bortezomib
  • Dexamethasone
  • Frontline
  • Induction therapy.
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this